News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Introgen Preclinical Studies Indicate Therapeutic Potential of INGN 241 In Lung Cancer (PR Newswire)...``The ability of the mda-7 gene to suppress the growth of lung tumors in a preclinical setting had not been shown before,......``These studies have demonstrated that INGN 241 may have both anti-tumor and anti-angiogenic activities.......Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain and breast cancer....- Mar 29 7:30 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/010329/dath015.html

Posted on: 03/29/2001

"Yahoo - Introgen Preclinical Studies Indicate Therapeutic Potential of INGN 241 In Lung Cancer"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
INGN
3 7/8
+1/32
delayed 20 mins - disclaimer
Thursday March 29, 7:30 am Eastern Time

Press Release

SOURCE: Introgen Therapeutics, Inc.

Introgen Preclinical Studies Indicate Therapeutic Potential of INGN 241 In Lung Cancer

Results Presented at the American Association for Cancer Research Meeting

AUSTIN, Texas, March 29 /PRNewswire/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - news) announced today that its gene therapy product candidate INGN 241, Adenoviral-mda7, may offer potential benefits in the treatment of lung cancer. Sunil Chada, Ph.D., director of research and development for Introgen presented the results of a preclinical study in a poster session at the 92nd Annual Meeting of the American Association for Cancer Research. Earlier this year, Introgen announced that it was awarded a Small Business Innovation Research grant from the National Cancer Institute, which is funding this collaborative lung cancer research between Introgen and The University of Texas M. D. Anderson Cancer Center.

"The ability of the mda-7 gene to suppress the growth of lung tumors in a preclinical setting had not been shown before," said Dr. Chada. "These studies have demonstrated that INGN 241 may have both anti-tumor and anti-angiogenic activities. The findings of this research complement our increasingly sophisticated understanding of mda-7 mechanisms of action. We will integrate the new discoveries into the design of our ongoing clinical programs with this drug."

The preclinical studies evaluated the use of INGN 241 in non-small cell lung cancer cells and their normal counterparts. Cell culture studies showed that INGN 241 selectively and potently killed tumor cells via apoptosis, a natural cell death pathway. Normal lung cells were not affected. When INGN 241 was used to treat human lung tumors in vivo, tumor growth was significantly inhibited. Additionally, the treatment stimulated the expression of important proteins responsible for cell death, including TRAIL and caspase 3, indicating that the in vivo properties of INGN 241 are similar to those seen in cell culture studies. These studies were conducted in collaboration with Rajagopal Ramesh, Ph.D. and Jack A. Roth, M.D. of the Department of Thoracic and Cardiovascular Surgery at The University of Texas M. D. Anderson Cancer Center.

Introgen is a leader in the development and production of gene-based drugs for the treatment of cancer and other diseases. Introgen's product candidates engage precise molecular targets to produce a highly specific therapeutic effect. Introgen specializes in combining appropriate gene delivery systems and therapeutic genes to make its gene-based drugs. Introgen's lead product candidate, INGN 201, is currently in Phase III clinical trials for the treatment of head and neck cancer. INGN 201 has been used in numerous clinical trials worldwide either alone or in combination with conventional treatments such as chemotherapy and radiotherapy. Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain and breast cancer. New applications using the human immune system with INGN 201 are being explored. Introgen's second product candidate, INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical development.

Certain statements in this press release that are not strictly historical may be "forward-looking" statements, which involve risks and uncertainties. Such forward-looking statements include, but are not limited to, those relating to safety and efficacy of drug product candidates, and the efficacy of our drug product candidates in treating lung cancer. There can be no assurance that Introgen will be able to commercially develop gene-based drugs, that necessary regulatory approvals will be obtained or that any clinical trials or studies undertaken will be successful or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgen's operations and business environment, including, but without limitation, Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, its dependence upon proprietary technology and current competition, history of operating losses and accumulated deficits, Introgen's reliance on collaborative relationships, and uncertainties related to clinical trials, safety, efficacy, the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission, including its prospectus dated October 12, 2000, filed with the Securities and Exchange Commission and the 10-Q filed with the Securities and Exchange Commission on February 14, 2001. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising from the date hereof.

     Contact:

     Introgen Therapeutics, Inc.
     C. Channing Burke
     (512) 708 9310 Ext. 322
     Email: c.burke@introgen.com

     Noonan/Russo Communications
     Lora Pike
     (415) 677 4455 Ext. 211
     Email: l.pike@noonanrusso.com

SOURCE: Introgen Therapeutics, Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Introgen Therapeutics Inc (NasdaqNM:INGN - news)
Related News Categories: biotech, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740